Biopharma
By
Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means for Biopharma’s Next Decade
A data-driven look at the first round of Medicare drug price negotiation, how it compares to the pricing…
Novartis’s U.S. Pricing Reckoning: How Generic Erosion and Growth-Brand Volume Are Reshaping the Post-Entresto Story
Analysis of Novartis’s Q2 2026 U.S. performance, the mechanics of its patent-cliff pricing headwind, and what it signals…
Pfizer’s $10 Billion Innovent Alliance: Is China Now the Epicenter of Next-Gen Cancer Drug Discovery?
Key Highlights A Broad Multidrug Alliance Built for Scale The agreement spans up to 12 programs, eight originating…
J&J’s $1 Billion Firefly Bio Buy: Has Big Pharma Finally Found a Way to Drug the ‘Undruggable’ KRAS?
Key Highlights A Novel Modality for a Notoriously Hard Target At the center of the acquisition is Firefly…
Merck and Moderna’s Melanoma Vaccine Win Could Be the Proof Point mRNA Oncology Has Been Waiting For
What the Phase 3 intismeran autogene + Keytruda results mean for the next wave of personalized cancer vaccines…
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma GLOBAL BIOPHARMA…
